Recent trials of T-cell depleted haploidentical hematopoeitic cell transplantation (HCT) suggest that NK cell reactivity can lead o less GVHD, reduced risks of relapse and improved overall survival when NK cells are NOT inhabited by recipient KIR ligands. In a cohort of Unrelated Donor (URD) HCT recipients at the University of Minnesota, no survival advantage was seen, suggesting that differences in clinical settings or other components of the relevant immunotiology may account for these disparate clinical results. The main hypothesis to be tested in this Program is that NK cells are of biologic importance in URD transplantation and that killer immunoglobulin-like receptor (KIR) interactions with MHC class 1 ligands can alter the clinical outcomes. This Program includes a group of international experts in NK cell biology and bone marrow transplantation collaborating to investigate the relevance of NK alloreactivity in URD HCT, a setting where KIR repertoires differ in nearly all donor-recipient pairs. We will utilize the many thousands of blood and DNA samples available through the National Marrow Donor Program (NMDP) and their high quality long-term follow-up data available on transplant outcomes. Project 1 will focus on the physiologic role of KIR differences inherent between donors and recipients using increasingly higher resolution of KIR determinations from simple gene content to haplotype organization. Novel KIR allele polymorphisms will be identified from these studies and their clinical significance will be determined. However, in many patients, KIR are not expressed normally after transplant. Therefore, in Project 2, NK cell development, the acquisition of functional KIR and the mechanisms that determine KIR expression will be studied. The retrospective NMDP cohort studies will facilitate immediate bedside to bench studies for Projects 1 and 2. In Project 3, prospective trials will exploit NK cell reactivity clinically and facilitate prospective evaluation of KIR genotype and KIR development based upon the work of Projects 1 and 2. Additionally, higher resolution KIR genotyping and matching will be studied for their impact on the risks of clinical complications after HCT. The synergistic interaction between all projects will take basic NK biology from the bench to the bee side to improve outcomes of URD HCT by better donor selection, KIR repertoire manipulation or enhancement of NK cell development. In addition to Administration (A) and Biostatistics (B) Cores, the projects are supported by scientific cores, each integrating with all projects for KIR genotyping (Core C), K.IR haplotype sequencing (Core D) and a KIR sequence public database (Core E). Taken together, these highly focused and integrated studies vv 11 definitively assess the role of NK cells and their receptors in URD IICT and broaden the success of alternative donor transplant, the only potentially curative therapy for many patients with advanced cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA111412-05
Application #
7669395
Study Section
Subcommittee G - Education (NCI)
Program Officer
Merritt, William D
Project Start
2005-08-17
Project End
2010-07-31
Budget Start
2009-08-11
Budget End
2010-07-31
Support Year
5
Fiscal Year
2009
Total Cost
$2,105,144
Indirect Cost
Name
University of Minnesota Twin Cities
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
555917996
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Grzywacz, Bartosz; Moench, Laura; McKenna Jr, David et al. (2018) Natural Killer Cell Homing and Persistence in the Bone Marrow After Adoptive Immunotherapy Correlates With Better Leukemia Control. J Immunother :
Sarhan, Dhifaf; Hippen, Keli L; Lemire, Amanda et al. (2018) Adaptive NK Cells Resist Regulatory T-cell Suppression Driven by IL37. Cancer Immunol Res 6:766-775
Williams, Robin L; Cooley, Sarah; Bachanova, Veronika et al. (2018) Recipient T Cell Exhaustion and Successful Adoptive Transfer of Haploidentical Natural Killer Cells. Biol Blood Marrow Transplant 24:618-622
Don Yun, Hyun; Felices, Martin; Vallera, Daniel A et al. (2018) Trispecific killer engager CD16xIL15xCD33 potently induces NK cell activation and cytotoxicity against neoplastic mast cells. Blood Adv 2:1580-1584
Cooley, Sarah; Parham, Peter; Miller, Jeffrey S (2018) Strategies to activate NK cells to prevent relapse and induce remission following hematopoietic stem cell transplantation. Blood 131:1053-1062
Williams, Shelly M; Sumstad, Darin; Kadidlo, Diane et al. (2018) Clinical-scale production of cGMP compliant CD3/CD19 cell-depleted NK cells in the evolution of NK cell immunotherapy at a single institution. Transfusion 58:1458-1467
Romee, Rizwan; Cooley, Sarah; Berrien-Elliott, Melissa M et al. (2018) First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation. Blood 131:2515-2527
Oh, Felix; Todhunter, Deborah; Taras, Elizabeth et al. (2018) Targeting EGFR and uPAR on human rhabdomyosarcoma, osteosarcoma, and ovarian adenocarcinoma with a bispecific ligand-directed toxin. Clin Pharmacol 10:113-121
Rashidi, Armin; Ebadi, Maryam; Said, Bassil et al. (2018) Absence of early HHV-6 reactivation after cord blood allograft predicts powerful graft-versus-tumor effect. Am J Hematol :
Bachanova, Veronika; Sarhan, Dhifaf; DeFor, Todd E et al. (2018) Haploidentical natural killer cells induce remissions in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells. Cancer Immunol Immunother 67:483-494

Showing the most recent 10 out of 108 publications